Biotechnology
TikoMed's drug candidate ILB® inhibited infection of human cells by Dengue, Zika and Yellow Fever viruses in vitro, providing further support for its broad spectrum mechanism of action
VIKEN, Sweden, Sept. 7, 2022 /PRNewswire/ -- TikoMed today announced the inclusion in bioRxiv* of an in vitro study examining the ability of the company's lead drug candidate ILB® to inhibit infection of human cells by four serotypes of Dengue virus (DENV1-4), two strains of Zika virus (African a...
Non-invasive skin immune biomarker test helps predict development of eczema in babies, new study presented at the EADV Congress finds
MILAN, Sept. 7, 2022 /PRNewswire/ -- Researchers have identified an immune biomarker in newborns that can predict the subsequent onset and severity of paediatric atopic eczema, a new study presented at the 31st European Academy of Dermatology and Venereology (EADV) Congress has shown. The Barrie...
Hummingbird Bioscience to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
SAN FRANCISCO, Sept. 6, 2022 /PRNewswire/ -- Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced that Chief Executive OfficerPiers Ingram, Ph.D., and Chief Financial Office...
Innovent Announces First Participant Dosed in the Higher-dose Cohort of a Phase 2 Clinical Trial of Mazdutide in Chinese Adults with Obesity
ROCKVILLE, Md. and SUZHOU, China, Sept. 5, 2022 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and ...
Aston Sci. Receives IND Approval from U.S. FDA for Phase 2 Clinical Trial of the Therapeutic Cancer Vaccine AST-301 in Patients with HER2 1+/2+ Breast Cancer
- CornerStone-001(NCT05163223), the multiregional clinical trial for breast cancer treatment, received U.S. FDA approval for Phase 2 trial following the approvals inAustralia and the Taiwan region. - As the same patient group and design of a pivotal study are adopted, a placebo-controlled randomi...
Antengene Announces XPOVIO® Included for Reimbursement by the PBS in Australia for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma
* XPOVIO® (selinexor) is the first and only selective inhibitor of nuclear export (SINE) inhibitor approved by the Therapeutic Goods Administration (TGA) ofAustralia for patients with relapsed and/or refractory multiple myeloma (R/R MM) and intriple class refractory R/R MM. * XPOVIO® is the f...
Brii Biosciences Appoints Taiyin Yang to Board of Directors, Strengthening Product Quality Oversight to Support Company Momentum
Addition increases diversity of Board governance and supports further
independent expertise
DURHAM, N.C. and BEIJING, Sept. 1, 2022 /PRNewswire/ -- Brii Biosciences
Broncus (02216.HK) announced interim results
The operating revenue had a year-on-year increase by 12.8% in 2022, and the loss narrowed by 62.8%, gradually forming a closed-loop model of "diagnosis + treatment+ chronic disease management" for major pulmonary diseases HANGZHOU, China, Aug. 31, 2022 /PRNewswire/ -- On August 30, 2022, Broncus ...
Mayo Clinic, Hibiscus BioVentures and Innoforce Announce Mayflower Cell and Gene Therapy Accelerator
ROCHESTER, Minn. and ROCKVILLE, Md., Aug. 31, 2022 /PRNewswire/ -- Mayo Clinic, Hibiscus BioVentures (Hibiscus) and Innoforce announce the launch of Mayflower BioVentures, a cell and gene therapy accelerator dedicated to identifying and forming companies around technologies that address unmet pat...
Quris Earns Frost & Sullivan 2022 Europe Technology Innovation Leadership Award for AI-Powered Drug Safety Prediction
Analysts found that the Quris Bio-AI Clinical Prediction Platform enhances drug development process agility, shortens discovery timelines, increases drug safety, and improves drug pipeline diversification opportunities SAN ANTONIO, Aug. 31, 2022 /PRNewswire/ -- Frost & Sullivan recently research...
TikoMed's ILB® mobilizes and modulates key growth factors that trigger a cascade of neuroprotective mechanisms able to target all neuroinflammation-driven diseases including ALS
VIKEN, Sweden, Aug. 31, 2022 /PRNewswire/ -- TikoMed, a biopharmaceutical company focused on harnessing the medical potential of the body's ability to self-repair and regenerate, today announced the publication in Frontiers in Phamacology of peer-reviewed research supporting the unique broad spec...
Antengene Announces Interim 2022 Financial Results and Provides Corporate Update
- Revenue of RMB 53.96 million mainly driven by the commercial launch of XPOVIO® (selinexor) in Mainland China onMay 13, 2022 - Adjusted loss reduced to RMB 126 million for the first six months of 2022 fromRMB 210 million in the same period last year - Cash and bank balances of RMB 2.151 billion...
Viva Biotech Announced 2022 Interim Results
Order Backlog Expected to Empower Future Growth with Increasing Long-term Competitive Advantages Financial Highlights for the 6 months ended June 30, 2022: * Revenue amounted to RMB1,108.7 million, representing a year-on-year ("YoY") increase of 8.0% * Gross profit amounted to RMB345.0 milli...
Minderoo Foundation and Illumina Commit $40M to Apply Advanced Genomics to Marine Conservation
New partnership will use the power of high-throughput sequencing to measure and understand marine life in our oceans at a rate that eclipses traditional research methods SAN DIEGO, Aug. 29, 2022 /PRNewswire/ -- Minderoo Foundation and Illumina, Inc. (NASDAQ: ILMN), today announced a40 million Au...
Sirnaomics Advances GalAhead(TM)-Based RNAi Therapeutics for Treatment of Complement-Related Diseases
GAITHERSBURG, Md. and SUZHOU, China, Aug. 26, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today the advancement of its GalAhead™ RNAi delivery platform f...
Kira Pharmaceuticals to Present New Preclinical Data on Lead Asset KP104 at the 2022 European Meeting on Complement in Human Disease Conference
Oral presentation characterizes promising PK/PD properties of KP104 in relevant animal models and supports its further development as a potent bifunctional complement inhibitor suitable for both intravenous and subcutaneous administration Poster presentations demonstrate synergistic effects of s...
CStone Pharmaceuticals Reports 2022 Interim Results and Business Updates
SUZHOU, China, Aug. 25, 2022 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today reported 2022 interim financial results an...
BGI Group Included in First Fortune China ESG List
SHENZHEN, China, Aug. 23, 2022 /PRNewswire/ -- BGI Group is featured among the top companies inChina in Fortune China's inaugural China ESG list, published this week. As Fortune China notes in their introduction to the list of 40 featured companies, they were delighted to find that although...
AtomVie Global Radiopharma Inc. Announces its Spinout and Series A Financing with Avego
HAMILTON ON, Aug. 24, 2022 /PRNewswire/ -- AtomVie Global Radiopharma Inc. ("AtomVie") today announced the successful closing of its Series A financing with Avego Management, LLC ("Avego"), a healthcare investment firm. AtomVie is a global leading CDMO (Contract Development and Manufacturing Orga...
MGI Supports the Ministry of Health of Indonesia in the Country's Breakthrough National Genome Project
JAKARTA, Indonesia, Aug. 24, 2022 /PRNewswire/ -- MGI Tech Co. Ltd. (MGI), a global life science leader and innovator, today announced that the National Genome Project inIndonesia has selected MGI technology* as one of the technology providers for the first phase of its effort towards establishin...
Week's Top Stories
Most Reposted
LINKDOOD Breaks Language Barriers, Ushering a New Era for Cross-Border Romance
[Picked up by 326 media titles]
2024-04-29 06:00Dow showcases circular and innovative materials science solutions and industry collaborations at Chinaplas 2024
[Picked up by 291 media titles]
2024-04-30 10:11Puyuan Fashion Resort 2024: A Grand Unveiling of Global Trends and Local Heritage
[Picked up by 269 media titles]
2024-04-28 09:39Chinese new energy industry contributes to global green, low-carbon transition
[Picked up by 249 media titles]
2024-04-30 15:13New International Land-Sea Trade Corridor achieves rapid development
[Picked up by 246 media titles]
2024-04-28 10:24